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P53 and its family members have been implicated in the direct regulation of the vitamin
D receptor (VDR). Vitamin D- and p53-signaling pathways have a significant impact on
spontaneous or carcinogen-induced malignant transformation of cells, with VDR and p53
representing important tumor suppressors. VDR and the p53/p63/p73 proteins all function
typically as receptors or sensors that turn into transcriptional regulators upon stimulus,
with the main difference being that the nuclear VDR is activated as a transcription factor
after binding its naturally occurring ligand 1,25-dihydroxyvitamin D with high affinity while
the p53 family of transcription factors, mostly in the nucleoplasm, responds to a large
number of alterations in cell homeostasis commonly referred to as stress. An increasing
body of evidence now convincingly demonstrates a cross-talk between vitamin D- and
p53-signaling that occurs at different levels, has genome-wide implications and that should
be of high importance for many malignancies, including non-melanoma skin cancer. One
interaction involves the ability of p53 to increase skin pigmentation via POMC derivatives
including alpha-MSH and ACTH. Pigmentation protects the skin against UV-induced DNA
damage and skin carcinogenesis, yet on the other hand reduces cutaneous synthesis of
vitamin D. A second level of interaction may be through the ability of 1,25-dihydroxyvitamin
D to increase the survival of skin cells after UV irradiation. UV irradiation-surviving cells
show significant reductions in thymine dimers in the presence of 1,25-dihydroxyvitamin
D that are associated with increased nuclear p53 protein expression, and significantly
reduced NO products. A third level of interaction is documented by the ability of vitamin
D compounds to regulate the expression of the murine double minute 2 (MDM2) gene in
dependence of the presence of wild-type p53. MDM2 has a well-established role as a key
negative regulator of p53 activity. Finally, p53 and family members have been implicated
in the direct regulation of VDR. This overview summarizes some of the implications of the
cross-talk between vitamin D- and p53-signaling for carcinogenesis in the skin and other
tissues.
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SKIN, VDR AND THE VITAMIN D ENDOCRINE
SYSTEM/REGULATORY NETWORK: AN INTRODUCTION
The skin is the largest organ of the human body, consisting of
several compartments that are named epidermis, dermis and sub-
cutis. The epidermis contains a basal layer (stratum basale), that
is composed of self-renewing cells (keratinocytes) with limited
proliferative capacity (transient amplifying cells), of stem cells
with high proliferative capacity that need to be preserved, and of
outwardly migrating layers (stratum spinosum, stratum granu-
losum and stratum corneum) of mostly resting keratinocytes at
different stages of differentiation. The skin is one of the key tis-
sues of the human body’s vitamin D regulatory network (VDRN)
(Lehmann et al., 2004; Holick, 2007; Reichrath and Reichrath,
2012; Mason and Reichrath, 2013). First, vitamin D is synthe-
sized in the skin (Figure 1) by the action of solar or artificial
ultraviolet B (UVB) radiation (under most living conditions,
only a small amount of vitamin D is taken up by the diet)
(Lehmann et al., 2004; Holick, 2007). Second, the skin repre-
sents an important target tissue for 1,25-dihydroxyvitamin D, the
biologically active natural vitamin D metabolite, that is formed
from vitamin D by consecutive hydroxylations at position 25
in the liver (mediated by CYP2R1 and by CYP27A1, resulting
in 25-hydroxyvitamin D) and at position 1 in the kidneys and
in many other tissues (mediated by CYP27B1) (Lehmann et al.,
2004; Holick, 2007; Reichrath and Reichrath, 2012; Mason and
Reichrath, 2013). 1,25-Dihydroxyvitamin D represents a potent
seco-steroid hormone that regulates, via various independent
mechanisms growth, many non-malignant and malignant cell
types, including human keratinocytes (Lehmann et al., 2004;
Holick, 2007; Haussler et al., 2012; Reichrath and Reichrath, 2012;
Mason and Reichrath, 2013). It exerts its effects through the bind-
ing with high affinity to a corresponding receptor (VDR) that
is located intranuclear in target tissues (Lehmann et al., 2004;
Holick, 2007; Haussler et al., 2012; Reichrath and Reichrath,
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FIGURE 1 | Schematic illustration of the vitamin D metabolism in human skin. Please note that, in contrast to fibroblasts, keratinocytes possess the
enzymatic machinery for the complete synthesis of 1,25-dihydroxyvitamin D from 7-dehydrocholesterole (7-DHC).
2012; Mason and Reichrath, 2013). VDR is a member of a
superfamily named trans-acting transcriptional regulatory fac-
tors, that also contains the retinoic acid receptors (RARs) and the
retinoid-X receptors (RXRs), as well as the thyroid and steroid
hormone receptors (Lehmann et al., 2004; Holick, 2007; Haussler
et al., 2012; Reichrath and Reichrath, 2012; Mason and Reichrath,
2013). The farnesoid-X receptor (FXR) that controls bile acid
metabolism and the pregnane-X receptor (PXR) which regulates
xenobiotic detoxification are evolutionarily most closely related
to the VDR (Haussler et al., 2012). Binding of its ligand 1,25-
dihydroxyvitamin D induces conformational changes of the VDR
that lead to heterodimerization with RXR and to zinc finger-
mediated binding to vitamin D response elements (VDREs)
that are located in regulatory regions of target genes (Haussler
et al., 2012). As a result, vitamin D activity in a particular cell
largely depends upon sufficient expression of VDR and RXR
proteins, the autocrine/paracrine production or the endocrine
delivery of adequate amounts of the 1,25-dihydroxyvitamin D
ligand, and of cell-specific programming of gene transcription
to regulate expression of distinctive genes that encode proteins
that finally exert the vitamin D effect (Haussler et al., 2012).
cDNA microarray analyses of mRNAs and other investigations
suggest that as many as 500–1000 coding genes may be regu-
lated by the VDR, which may contact up to ∼8000 loci in the
human genome (Haussler et al., 2012). 1,25-Dihydroxyvitamin
D-mediated transcriptional regulation of many genes involved
in cellular growth and differentiation has been demonstrated,
including the genes for ß3-integrin, fibronectin, and cell cycle reg-
ulatory proteins such as p21/WAF-1 (CDKN1A) (Lehmann et al.,
2004; Holick, 2007; Haussler et al., 2012). Like most other skin
cells, keratinocytes express VDR (Lehmann et al., 2004; Holick,
2007); in these cells, 1,25-dihydroxyvitamin D, blocks prolifera-
tion and promotes differentiation in vitro (Lehmann et al., 2004;
Holick, 2007; Haussler et al., 2012). Interestingly, it has been
reported that the combination of 1,25-dihydroxyvitamin D and
the retinoic acid metabolite isotretinoin is efficient in the therapy
of precancerous skin lesions and of non-melanoma skin cancer
(cutaneous squamous and basal cell carcinomas) (Tang et al.,
2012a,b; Mason and Reichrath, 2013). Moreover, it has been
demonstrated that VDR ablation promotes chemically induced
skin carcinogenesis (Tang et al., 2012a,b; Mason and Reichrath,
2013).
VDR-signaling comprises much more than just ligand/
receptor triggering of gene expression. Distinct and fine-tuned
responses indicate a complex regulation of this signaling path-
way. Moreover, chemical and other modifications of the VDR
signaling pathway govern such important parameters as intracel-
lular trafficking, duration of interaction between the receptor and
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cofactors, the receptor and ligand, as well as turnover and stability
of other relevant proteins (Haussler et al., 2012). Not least, regu-
lation of VDR target genes is controlled by stability and turnover
of relevant microRNAs and RNAs (Haussler et al., 2012).
Depending on cell type and context, both VDR- and
p53-signaling regulate many cellular functions that are of rel-
evance for cancer development, including proliferation, differ-
entiation, apoptosis and cell survival (Murray-Zmijewski et al.,
2006; Holick, 2007; McKeon and Melino, 2007; Vousden and
Lane, 2007; Vousden and Prives, 2009; Haussler et al., 2012;
Mason and Reichrath, 2013). Consequently, vitamin D- and
p53-signaling pathways have a significant impact on sponta-
neous or carcinogen-induced malignant transformation of cells,
with vitamin D receptor (VDR) and p53 representing important
tumor suppressors (Murray-Zmijewski et al., 2006; Holick, 2007;
McKeon and Melino, 2007; Vousden and Lane, 2007; Vousden
and Prives, 2009; Haussler et al., 2012; Mason and Reichrath,
2013). Mutations in genes encoding for proteins of the p53 path-
way represent a hallmark of many if not all types of cancer
(Vousden and Lane, 2007; Vousden and Prives, 2009). Low serum
25(OH)D concentrations and distinct polymorphisms (SNPs) in
the VDR gene and other vitamin D-related genes, on the other
hand, are associated with an increased incidence and an unfa-
vorable outcome of various malignancies (Mason and Reichrath,
2013). The VDR and the p53 family all function typically as acti-
vatable transcriptional regulators, with the main difference being
that VDR is activated after binding its naturally occurring lig-
and 1,25-dihydroxyvitamin D (1,25(OH)2D or calcitriol) with
high affinity (Haussler et al., 2012) while p53, mostly in the
nucleoplasm, responds to a large and still growing number of
alterations in cell homeostasis (Murray-Zmijewski et al., 2006;
McKeon and Melino, 2007; Vousden and Lane, 2007; Vousden
and Prives, 2009). In any event is the result of such activation—
manifested by conformational changes and heterodimerization
with retinoid X receptor (RXR) of VDR and by chemical modifi-
cations and oligomerization of the p53 family—the direct contact
with regulatory DNA. In both pathways the cell type- and context-
dependent recruitment of nuclear co-regulators entails the stim-
ulation or repression of a very large number, typically hundreds,
of genes (Lin et al., 2005; Holick, 2007; Perez and Pietenpol,
2007; Sbisa et al., 2007; Riley et al., 2008; Haussler et al., 2012).
Several of these code themselves for transcriptional regulators,
adding a further level of complexity to the networks. It is obvious
that transcription factor pathways may cross-talk, for instance,
through the sharing of target genes or co-regulators, and through
the engagement in interdependent regulatory loops. Indeed, all of
these mechanisms, plus several others, seem to have been realized
in the cross-talk of VDR and the p53 family (Table 1).
Intriguingly, both pathways are critically involved in cellu-
lar processes that are important for carcinogenesis such as cell
differentiation/proliferation, in the regulation of stem cell main-
tenance, and in cell homeostasis. While VDR controls prolifer-
ation/differentiation of many cell types (Holick, 2007; Haussler
et al., 2012), some members and isoforms of the p53 family, and
in particular p53 itself, reduce the stem cell potential and stimu-
late differentiation (Lin et al., 2005). Interestingly, on the side of
the p53 family, all three members (p53/p63/p73) can be expressed
as truncated isoforms capable of counteracting their siblings’
transactivating effects (Murray-Zmijewski et al., 2006). Not too
surprising, VDR and p53 have been linked to many malignan-
cies, including non-melanoma skin cancer (Mason and Reichrath,
2013). The present review aims at providing an overview on this
interesting signaling network, with a focus on non-melanoma
skin cancer. Future genome-wide analyses of the target genes will
shed further light on the interaction of these pleiotropic regula-
tors. Before the cross-talk is discussed, the p53 pathway shall be
briefly outlined.
THE p53 FAMILY OF TRANSCRIPTIONAL REGULATORS
p53, p63, and p73 (the p53 family hereafter) are homotetrameric
transcriptional regulators that bind to very closely related
DNA motifs, consisting of two consecutive 10-mers (half-sites),
Table 1 | Overview of the cross talk between vitamin D- and p53 signaling.
Crooss talk/interaction Mechanism References
p53 modulates cutaneous
vitamin D synthesis
p53 upregulates skin pigmentation via POMC derivatives including
alpha-MSH and ACTH.
Rev. in Yamaguchi and Hearing, 2009 (77)
p53 regulates VDR
expression
p53 and its family members have been implicated in the direct regulation
of the VDR.
Maruyama et al., 2006 (97)
p53 protein binds to highly conserved intron-sequences of the VDR gene. Kommagani et al., 2007 (96)
1,25-D increases survival
of UV-irradiated skin cells
Significant reductions in thymine dimers in the presence of 1,25-D in
UV-irradiated, surviving cells that are associated with increased nuclear
p53 protein expression.
Gupta et al., 2007 (78)
1,25-D regulates MDM2
expression
Dependent on presence of wild type p53, 1,25-D regulates expression of
the MDM2 gene.
Chen et al., 2013 (79)
Interaction between VDRE and p53Res in the P2 promoter region of the
MDM2 gene.
1,25-D, 1,25-dihydroxyvitamin D; MDM2, murine double minute 2.
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preferentially spaced by no more than zero to 2 base pairs,
with the consensus r,r,r,C,A/T,T,G,y,c,y (p53); r,r,r,C,G,T,G,y,y,y;
t/a,a/t,a,C,A/T,T,G,t,t/a,t or r,r,r,C,A/G,T/A,G,y,y,y (p63), and
a/c/g,g/a,g,C,A,T,G,c/t,c,c/t (p73; r = purines; y = pyrimidines)
(Osada et al., 2005; Riley et al., 2008; Brandt et al., 2009; Roemer,
2012). They share a large number of target sequences, as expected
given the high degree of homology within the DNA binding
domains, among the consensus sequencemotifs, and the degener-
acy of the individual binding sites (Roemer, 2012). It is therefore
perhaps no surprise that the regulation of a defined sequence
by any of these transcription factors is controlled at several lev-
els including posttranslational modifications and protein/protein
interactions. Many of these are specific for each family paralog.
Moreover, the binding of p53, p63, and p73 to DNA is affected by
additional parameters such as the number of the half-sites, their
orientation, their position relative to the target gene, and their
overlap with binding sites for other transcription factors. Finally,
differential recruitment of co-activator/co-repressor complexes to
promoters has been documented. These may be coded, for exam-
ple, by specific spacings between the 10-mers of the DNA binding
motifs (Riley et al., 2008). Epigenetic CpG methylation does not
seem to affect the binding to DNA significantly (Brandt et al.,
2009; Roemer, 2012).
The p53 family proteins display a modular organization that
is quite different from that of the VDR (see above). Typically, an
N-terminal transactivation domain (TD), a central DNA binding
domain (DBD) and C-terminal regulatory and protein/protein
interaction domain is present. The DBDs are the most highly
conserved regions among the paralogs, sharing ∼60% homology
(Murray-Zmijewski et al., 2006; Roemer, 2012). In addition to the
full-length variants, a large number of isoforms exists, owing to
transcription initiation from internal promoters, alternative splic-
ing and the use of alternative translation initiation sites; however,
in most cases the DBD is maintained. More than 10 different
isoforms of p53, more than six of p63 and at least 29 of p73
are currently known (Murray-Zmijewski et al., 2006; Hollstein
and Hainaut, 2010; Roemer, 2012). In most cases, their biolog-
ical functions are not fully understood. Furthermore, an arsenal
of posttranslational modifications that are in part interdepen-
dent has evolved. These include phosphorylations, acetylations,
ubiquitinations, sumoylations, neddylations, methylations, gly-
cosylations, and oxidation/reduction, and they control the pro-
teins’ abundance, DNA binding, level of activity as transcription
factor, cross-talk with other proteins and subcellular localization
(Murray-Zmijewski et al., 2006; Toledo and Wahl, 2006; Kruse
andGu, 2009). All these levels of regulation are best studied in p53
and have revealed an enormous degree of complexity (Vousden
and Prives, 2009; Roemer, 2012) which may be exemplified by the
chemical modification “code” that seems to regulate p53 func-
tion in a tissue-specific manner through the sequential build-up
of poly-phosphorylation patterns at different sites and that may
even be accompanied by other chemical changes such as acetyla-
tions (Gu and Roeder, 1997; Ashcroft et al., 2000; Wang et al.,
2004; Roemer, 2012). At the level of the cell, p53 is involved
in the regulation of the cell cycle (Wang and El-Deiry, 2006),
cell survival and autophagy, DNA repair, respiration, oxidative
stress protection, glucose metabolism, cell adhesion/motility, the
cytoskeleton and endo/exosome compartments, and of angiogen-
esis. At the organismal level, p53 is involved in tumor suppression
and maintenance of genome stability, and the control of stem
cell compartments, female fertility and ageing (Riley et al., 2008;
Roemer, 2012).
The complexity of the regulation of the p53 family is further
highlighted by the antagonistic partnership between p53 and its
central negative regulators, the E3 ubiquitin ligases murine dou-
ble minute 2 (MDM2) and MDM4 (Roemer, 2012). Activation
of p53 is almost always involving inhibition of MDM2/4. For
example, acetylation of p53 andMDM2 overcomes the inhibitory
ubiquitination of p53 by MDM2 through the blocking of MDM2
enzymatic function, the dissociation of the p53/MDM2 complex
and thereby, the stimulation of p53’s interaction with DNA as
well as the recruitment of co-activators (Gu and Roeder, 1997;
Ashcroft et al., 2000; Wang et al., 2004; Roemer, 2012). MDM4 is
not functioning as a ubiquitin ligase for p53 but can inhibit p53’s
transcriptional activity and modulate the p53/MDM2 interaction
(Toledo and Wahl, 2006; Roemer, 2012). Since p53 can transacti-
vate the MDM2 gene, a negative feedback loop is formed (Toledo
andWahl, 2006; Kruse and Gu, 2009; Roemer, 2012). Such a loop
is also established with p63 and p73; however, MDM2 inhibits
these transcription factors at promoters yet in contrast to p53
cannot ubiquitin-mark them for degradation (Murray-Zmijewski
et al., 2006; Roemer, 2012).
Cell context determines the respective function of individual
p53 family members. In the absence of extra stress, i.e., under
physiological background stress induced, for instance, by reac-
tive oxygen species (ROS) as a by-product of respiration, p53,
p63, and p73 primarily control cell fate, differentiation and devel-
opment. Intriguingly, these functions seem to be predominantly
mediated by the DNA binding competent yet transactivation
impaired delta-N isoforms of the proteins (Np63, Np73).
In cells or tissue that have been challenged by further stresses,
as for example by overt ROS production, radiation, hypoxia,
hypo/hyperthermia, metabolite shortages and imbalances, onco-
gene dysregulation, and virus/bacterial/parasite infections, the
p53 family members, and in particular p53 itself, seem to mainly
control repair, proliferative capacity and survival. Central to
these functions are the transactivation-proficient isoforms (p53,
TAp63, TAp73). Since many of the damaging stresses can support
cell transformation, the p53 family, and here again, mostly p53
itself, thus act as tumor suppressors by inducing cell cycle arrest,
temporary or permanent senescence, apoptosis, and differentia-
tion (Vousden and Lane, 2007; Levine and Oren, 2009; Vousden
and Prives, 2009; Roemer, 2012). Conversely, lack of proper func-
tion of p53 or p73, or overproduction of dominant-negative
Np63, support tumor formation in animals and humans. Along
the same line, tumor-inducing viruses encode proteins that target
p53, and perhaps there is no tumor in which the p53 path-
way itself plus all ascending/descending pathways are fully intact
(Gatza et al., 2007; Vousden and Lane, 2007; Feng et al., 2008; Hu
et al., 2008; Roemer, 2012).
Like p53, p63, and p73 can act as tumor suppressors, although
this does not seem to be their primary functions (Murray-
Zmijewski et al., 2006; Roemer, 2012). For example, p63 and
p73 are not as frequently mutated in human cancers as is p53.
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Rather, p63 is often overproduced in tumors (Park et al., 2000),
which seems to contradict its function as a tumor suppressor,
yet as mentioned above, this is often due to p63 isoforms that
lack the transactivation domain but not their ability to bind
to DNA and that thereby may act dominant-negatively (Candi
et al., 2007; Roemer, 2012). In contrast and as expected from a
tumor suppressor, transactivation competent p63 (TAp63) can
sensitize cells to apoptosis in response to DNA damaging stress
(Gressner et al., 2005; Roemer, 2012). Moreover, some p63±mice
are tumor-prone, and the resulting tumors often display loss of
the remaining wild-type allele (Flores, 2007; Roemer, 2012). Mice
with a specific deficiency for TAp73 show genomic instability and
a higher tumor incidence (Tomasini et al., 2008; Roemer, 2012).
Furthermore, p63 and p73 seem to have p53-independent roles in
DNA repair (Talos et al., 2007; Lin et al., 2009; Roemer, 2012).
p63 and p73, but not p53, are crucial for embryonic devel-
opment in all organisms examined so far (Danilova et al.,
2008; Roemer, 2012). Although p53-deficiency interferes with
mesoderm/endoderm fate determination in the frog Xenopus
(Wallingford et al., 1997; Roemer, 2012), this condition fails to
generate significant early phenotypes in mice or humans (Choi
and Donehower, 1999; Varley, 2003; Roemer, 2012). However,
at a more subtle level, and since p53 can induce stem cell
differentiation, lack of p53 function may cause unrestrained
stem cell proliferation (Gil-Perotin et al., 2006; Dumble et al.,
2007; Roemer, 2012). Other more subtle functions of p53 are
in mitochondrial respiration and glucose metabolism (Matoba
et al., 2006; Roemer, 2012). Overactivity of p53, by contrast,
does indeed entail immediate and dramatic consequences in the
development of the early mouse embryo—its apoptotic loss—
and one of the most striking functions of the p53 inhibitors
MDM2 and MDM4 during embryonic development is the pre-
vention of this consequence (Marine et al., 2006; Roemer, 2012).
Later in embryonal development, for example during neurogene-
sis, the DNA binding-proficient yet transactivation-incompetent
dominant-negative isoform of p73, Np73, may serve as a p53
and p63 restraining factor to inhibit apoptosis (Jacobs et al., 2004;
Roemer, 2012). p53 and possibly p63, but most importantly p73,
help shape the nervous system during life, perhaps primarily by
controlling apoptosis (Jacobs et al., 2005;Miller and Kaplan, 2007;
Roemer, 2012).
p63 function during development is critical for epithelial
stem cell maintenance (Yi et al., 2008; Roemer, 2012), squamous
epithelial differentiation and skin renewal (Truong et al., 2006;
Koster et al., 2007; Mikkola, 2007; Roemer, 2012). The Np63
isoform acts mainly through controlling the expansion of epithe-
lial layers while TAp63 seems to support differentiation, and it
functions as the guardian of the female germ line by inducing
apoptosis in damaged resting oocytes (Suh et al., 2006; Roemer,
2012). p73 deficiency in mice results in neuronal and olfactory
dysfunctions as well as in chronic infection and inflammation
(Murray-Zmijewski et al., 2006; Roemer, 2012). Collectively, the
stem cell/differentiated cell decision seem to be regulated in part
by the balance between the Np63/TAp63 antagonists in the
skin and - in an analogous manner - by the balance between
the Np73/TAp73 antagonists in the developing nervous and
immune systems. Thus, p73may be to neuronal development and
homeostasis what p63 is to the development and homeostasis of
the skin (De Laurenzi et al., 2000; Jacobs et al., 2004; Roemer,
2012). Since the pleiotropic VDR is important for tumor suppres-
sion as well as skin development and differentiation, it is perhaps
no surprise that both transcriptional regulator pathways talk to
each other.
CROSS-TALK BETWEEN THE VDR AND THE p53 FAMILY IN
CANCER
An increasing body of evidence points to a cross-talk between
vitamin D- and p53-signaling occuring at different levels that
might be of great importance for many malignancies, including
non-melanoma skin cancer (Table 1). Both p53 and VDR act as
tumor suppressors in several tissues, including skin. Much of the
tumor suppressor function in the skin may be mediated through
the interaction of the VDR and p53 pathways—either by mutual
activation or inhibition. What is known about this interaction, in
particular in non-melanoma skin cancer? DNA damage induced
by solar or artificial ultraviolet (UV) radiation represents themost
important environmental risk factor for carcinogenesis of cuta-
neous squamous cell carcinoma (SCC) (Reichrath and Reichrath,
2012; Mason and Reichrath, 2013). The predominant types of
DNA damage which are directly induced by UV are promutagenic
pyrimidine dimers (Wikonkal and Brash, 1999; Reichrath and
Reichrath, 2012; Mason and Reichrath, 2013). Thymine-thymine
dimers, which represent cys-syn cyclobutane pyrimidine dimers
(CPDs), are the major form of pyrimidine dimers that are identi-
fied in human skin following UV-B exposure. In contrast, other
types of DNA damage, including cytosine-cytosine, thymine-
cytosine bipyrimidines, and 6–4 photoproducts are less frequently
detected (Douki et al., 2000; Cooke et al., 2003; Courdavault et al.,
2004a; Mouret et al., 2006; Reichrath and Reichrath, 2012; Mason
and Reichrath, 2013). CPDs are caused via disruption of the 5–6
double bonds in two adjacent pyrimidine bases, thereby induc-
ing atypical covalent binding which connects the 2 bases by a
stable ring configuration, resulting in a bipyrimidine (Ravanat
et al., 2001; Pattison and Davies, 2006; Reichrath and Reichrath,
2012; Mason and Reichrath, 2013). In general, CPDs are induced
by UV-B (290–320 nm) (Reichrath and Reichrath, 2012; Mason
and Reichrath, 2013), although the production of thymine dimer
by UV-A (320–400 nm) wavelengths below 330 nm has also been
reported (Applegate et al., 1999; Jiang et al., 1999; Rochette et al.,
2003; Courdavault et al., 2004b; Mouret et al., 2006; Reichrath
and Reichrath, 2012; Mason and Reichrath, 2013). UV-radiation
induces gene mutations which may result in photocarcinogene-
sis (Hart et al., 1977; Sutherland et al., 1985; Brash et al., 1991;
Agar et al., 2004; Besaratinia et al., 2008; Reichrath and Reichrath,
2012; Mason and Reichrath, 2013). Moreover, it has been shown
that DNA damage initiates and promotes cellular mechanisms
which block the detection and elimination of transformed cells by
immune surveillance (Applegate et al., 1989; Kripke et al., 1992;
Reichrath and Reichrath, 2012; Mason and Reichrath, 2013).
UV radiation induces different forms of DNA lesions which are
generated either photochemically and directly or indirectly by
UV activation of several photoreceptors which have the capac-
ity to modulate the cellular redox equilibrium, thereby generating
reactive oxygen species (ROS) (Reichrath and Reichrath, 2012;
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Mason and Reichrath, 2013). ROS induced cellular damage then
leads both to oxidative DNA damage, and to lipid peroxidation
(Reichrath and Reichrath, 2012; Mason and Reichrath, 2013).
Additionally, UV-induced increased levels of nitric oxide synthase
(Deliconstantinos et al., 1995; Bruch-Gerharz et al., 1998; Cals-
Grierson and Ormerod, 2004; Reichrath and Reichrath, 2012;
Mason and Reichrath, 2013) cause excess levels of nitric oxide
(NO) (Paunel et al., 2005; Mowbray et al., 2009; Reichrath and
Reichrath, 2012; Mason and Reichrath, 2013). It has been shown
that these pathophysiologically increased concentrations of NO
and ROS combine to generate genotoxic NO products, including
peroxynitrite, which modify the bases and the sugar-phosphate
scaffold of DNA via nitrosative and oxidative damage (Reichrath
and Reichrath, 2012; Mason and Reichrath, 2013) Both UV- and
ROS-induced damages activate p53.
UV-irradiation induces p53 to stimulate skin pigmentation via
POMC derivatives including alpha-MSH and ACTH (Yamaguchi
and Hearing, 2009), thereby protecting the skin against further
UV-induced DNA damage and skin carcinogenesis. However, this
reduces cutaneous synthesis of vitamin D. This may be impor-
tant because, on a second level, 1,25-dihydroxyvitamin D can
increase the survival of UV-irradiated keratinocytes and prevent
further accumulation of DNA damage in these surviving skin
cells (Gupta et al., 2007). Following UVR, the survival of 1,25-
dihydroxyvitamin D-treated skin cells was significantly higher
as compared to vehicle-treated cells (P < 0.01) (Gupta et al.,
2007). In that study, UVR-surviving and 1,25-dihydroxyvitamin
D-treated keratinocytes showed significantly reduced levels of
thymine dimers (TDs) as compared to vehicle-treated cells (P <
0.001) (Gupta et al., 2007). Following UVR, nuclear p53 protein
levels were elevated and, notably, became elevated to signifi-
cantly higher levels in the presence of 1,25-dihydroxyvitamin
D (P < 0.01). In contrast, NO derivatives were significantly
decreased in 1,25-dihydroxyvitaminD-treated keratinocytes (P <
0.05) (Gupta et al., 2007). Both the elevated levels of nuclear p53
protein and the decreased production of nitric oxide products
were suggested to be responsible at least in part for the decrease
in TDs seen with 1,25-dihydroxyvitamin D-treatment after UVR
(Gupta et al., 2007). In addition, a reduction in the number of
TDs (P < 0.05) and in sunburn cells (P < 0.01) were demon-
strated in skin sections from Skh:hr1 mice that had been treated
with 1,25-dihydroxyvitamin D, at 24 h after UVR (Gupta et al.,
2007). It was concluded that the vitaminD system in skin, in com-
bination with p53, may represent an intrinsic mechanism that
protects against UV damage (Gupta et al., 2007).
As a further molecular level of interaction it has been demon-
strated that vitamin D compounds can regulate the expression of
theMDM2 gene in dependence of p53 (Chen et al., 2013). As out-
lined above,MDM2 represents a p53-inducible gene that encodes
an E3 ubiquitin ligase mainly responsible for the degradation of
p53 by the 26S proteasome (Roemer, 2012). A major function of
MDM2 is its role as a key negative feed-back regulator of p53
activity (Bond et al., 2004), p53 activates MDM2 expression via
binding to corresponding p53 response elements (p53REs) in the
P2 promoter of the MDM2 gene. The increase of MDM2 pro-
tein then leads to its binding to p53 (primarily at the N-terminal
1–52 residues), which causes degradation of p53 or inhibition
of p53 activity as a transcription factor (Chen et al., 1993).
Vitamin D may thus prevent a lasting and overt p53 response
in the face of damage and may thereby protect reparable cells
from p53-induced apoptosis. However, MDM2 also exerts many
p53-independent functions, and interacts with a broad variety
of other proteins (including insulin like growth factor receptor,
androgen receptor, estrogen receptor, Numb, RB, p300, etc.) that
are of importance for various cellular functions including pro-
liferation/differentiation, cell fate determination, and signaling
(Ries et al., 2000; Ganguli and Wasylyk, 2003; Steinman et al.,
2004; Zhang and Zhang, 2005; Lengner et al., 2006; Araki et al.,
2010). VDR may activate the MDM2 gene directly, through a
VDR-response element in the promoter P2 of the MDM2 gene
(Barak et al., 1994; Zauberman et al., 1995; Roemer, 2012; Chen
et al., 2013) However, even with this direct binding to MDM2
sequences, p53 seems to be required for the induction of MDM2
expression by VDR (Chen et al., 2013). Perhaps this is reflect-
ing a cross-talk between the VDR and p53 bound to DNA since
the p53 response element in the MDM2 gene is also located in
promoter P2.
VDR and p53 family members act first and foremost as tran-
scription factors, and accordingly, much of the highly complex
cross-regulation between them seems to happen at this level.
For example, members of the p53 family including Np63 can
modulate VDR signaling through competitive binding to various
VDR target genes including p21Waf1/Cip (CDKN1A). Multiple
VDREs have recently been identified in the promoter region of
the CDKN1A gene, which is a transcriptional target of p53 and
encodes a powerful blocker of the cell cycle in G1 and G2 phases
(Saramaki et al., 2006). Notably, like with the MDM2 gene, the
VDR and p53 binding sites are in close proximity in the CDKN1A
promoter (Saramaki et al., 2006). A much more detailed and
unbiased (pathway-independent) genome-wide analysis of the
VDR:p53 family interactions bound to DNA is in need. To this
end, it shall be useful to employ chromatin immunoprecipita-
tions (ChIPs) with either ChIPping with p53-antibodies first and
re-ChIPping with VDR antibodies, or vice versa. Also, knock-in
studies in which VDR response elements or p53 response ele-
ments in close proximity are deleted, should provide a deeper
insight into the cooperativity or antagonism between these
important tumor-suppressing transcription factors.
In the skin, p53/p63 play an important regulatory role in the
maintenance of the stem cells as well as in the establishment of
the differentiation gradient. In the undifferentiated proliferating
basal layer of the skin, the dominant negatively acting, because
DNA binding but transactivation impaired, Np63 rules. Most
effects exerted by the transactivation-competent p53 familymem-
bers are inhibited by it (Yang et al., 1998; Lee and Kimelman,
2002; Roemer, 2012) In addition, Np63 may inhibit differen-
tiation by the blunting of VDR signaling through binding to
various VDR target genes including CDKN1A (Pellegrini et al.,
2001; Westfall et al., 2003; Roemer, 2012) TAp63 that is minor
to Np63 in this proliferating compartment of the skin, may
become more dominant as Np63 levels decrease in the course
of differentiation (Nylander et al., 2002; Roemer, 2012).
Finally, p53 family members may regulate VDR directly
(Maruyama et al., 2006; Kommagani et al., 2007). In a
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comparative genomics investigation in the human and mouse
genome designed to locate conserved p53 binding sites, the VDR
and 31 other genes were newly described as putative p53 tar-
gets. Reverse transcription-PCR and real-time PCR confirmed
the responsiveness of these genes to p53 in human cancer cell
lines (Maruyama et al., 2006). It was shown that VDR is upreg-
ulated by p53 and some other members of the p53 family. For
example, an isoform of p63 (p63 gamma) can specifically upreg-
ulate VDR by directly associating with the VDR promoter in vivo
(Kommagani et al., 2007). Moreover, ChIP analysis demonstrated
that wild-type p53 protein binds to a conserved intronic site of the
VDR gene (Maruyama et al., 2006). Conversely, transfection of
VDR into cells resulted in upregulation of several p53 target genes
and in growth suppression of colorectal cancer cells. In addi-
tion and as discussed above, p53 stimulated several VDR target
genes in a 1,25-dihydroxyvitamin D-dependent manner, that is,
in cooperation with VDR (Maruyama et al., 2006). Future, whole
transcriptome-including studies will identify new transcripts that
are initiated by VDR and p53 in concert.
An increasing body of evidence highlights the relevance of the
cross-talk between VDR- and p53-signaling under various physi-
ological and pathophysiological conditions. One study identified
the VDRE as overrepresented in promoter sequences bound by
mutated p53 (mutp53), and showed that mutp53 can interact
functionally and physically with VDR (Stambolsky et al., 2010).
In that investigation, mutp53 was recruited to VDR target genes
and modulated their expression (increasing transactivation or
relieving repression) (Stambolsky et al., 2010). Moreover, mutp53
promoted the nuclear accumulation of VDR and converted 1,25-
dihydroxyvitamin D into an anti-apoptotic agent (Stambolsky
et al., 2010).
Several investigations analyzed the cross-talk between VDR-
and p53-signaling in bone. It was demonstrated that hepatocyte
growth factor (HGF) and 1,25-dihydroxyvitamin D act together
to induce osteogenic differentiation of human bone marrow stem
cells (hMSC) potentially through elevating p53 (Chen et al.,
2012). The authors of this study hypothesized that the com-
bination of HGF and 1,25-dihydroxyvitamin D can promote
hMSC differentiation by up-regulation of 1,25-dihydroxyvitamin
D and/or VDR expression to booster cell response(s) to 1,25-
dihydroxyvitamin D. In line with this hypothesis, it was shown
that HGF up-regulated gene expression of VDR and p63 and that
p63 gene knockdown by siRNA eliminated the effects of HGF
on VDR gene expression (Chen et al., 2012). Moreover, recent
findings suggest that the cross-talk of VDR and p53 may directly
target the human osteocalcin gene and positively affect osteocal-
cin gene expression. It was reported that osteocalcin promoter
activity can be up-regulated both by exogenous and endoge-
nous p53 and downregulated by p53-specific siRNA (Chen et al.,
2011). It was shown that p53 binds to the human osteocal-
cin promoter in vitro and a p53 response element within the
osteocalcin promoter region was identified (Chen et al., 2011).
In this investigation, an additive effect of p53 and VDR on
the regulation of osteocalcin promoter activity was observed.
Another study demonstrated that p73 acts as an upstream
regulator of 1,25-dihydroxyvitamin D-induced osteoblastic dif-
ferentiation (Kommagani et al., 2010). In that investigation,
silencing p73 significantly decreased 1,25-dihydroxyvitamin D-
mediated osteoblastic differentiation; although p73 induced by
DNA-damage increased 1,25-dihydroxyvitamin D-mediated dif-
ferentiation of osteosarcoma cells (Kommagani et al., 2010).
CONCLUSIONS AND PERSPECTIVES
VDR and the members of the p53 family are activatable tran-
scriptional regulators that are at the hub of a common molecular
network to control cell homeostasis, proliferation, differentiation
and survival, and that way, act as classical tumor suppressors.
Malfunction of either entails elevated susceptibility to transfor-
mation. A tissue archetypical of this interaction is the skin. Here,
VDR as well as p53 and p63 control differentiation and the main-
tenance of the stem cell compartment. Accordingly, damage to
skin cells such as induced by UV irradiation, or transformation
of skin cells, typically come with characteristic responses of these
proteins in the form of specific gene expression profiles to control
differentiation, proliferation and survival. Since both classes of
nuclear transcription factors act primarily through the regulation
of genes, it is thus no great surprise to find functional interaction
at several levels. Future, ChIP- and transcriptome analysis-based
genome-wide studies of the DNA sequences that are targeted indi-
vidually or by both factors together should provide us with new
insights into this fascinating network.
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